- Conditions
- Sepsis
- Interventions
- Muscle stimulation with Niveus medical stimulator, measurement of maximal isometric twitch strength, Muscle Biopsy, Muscle Biopsy Medication: Lidocaine, Muscle Biopsy Medication: Versed, Muscle Biopsy Medication: Fentanyl, Blood and Urine Sampling, ineffective muscle stimulation
- Device · Procedure · Drug + 1 more
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 3,527
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome
- Interventions
- Navitoclax, Venetoclax, Decitabine, Bone Marrow Biopsy, Biospecimen Collection, Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Pancreatic Carcinoma
- Interventions
- Non-Interventional Study
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 11
- States / cities
- Scottsdale, Arizona • San Francisco, California • Atlanta, Georgia + 8 more
- Conditions
- Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma
- Interventions
- Biopsy, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Glofitamab, Lenalidomide, Obinutuzumab, Positron Emission Tomography, Venetoclax
- Procedure · Biological · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- Duarte, California • New York, New York • Salt Lake City, Utah
- Conditions
- Fetal Lung Maturity, Respiratory Distress Syndrome in Premature Infant
- Interventions
- blood draw
- Other
- Lead sponsor
- Wayne State University
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 80 participants
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Breast Cancer Risk, Breast Cancer Prevention, Breast Cancer
- Interventions
- Saliva sample, Health Surveys
- Genetic · Other
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Piscataway, New Jersey
- Conditions
- Osteosarcoma
- Interventions
- Biospecimen Collection, Laboratory Biomarker Analysis, Questionnaire Administration
- Procedure · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 18 Years to 50 Years · Male only
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 93
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 76 more
- Conditions
- Influenza
- Interventions
- Fluzone®, FluMist®
- Biological
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 6 Months to 49 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
- Interventions
- Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Cyclophosphamide, Echocardiography Test, Lumbar Puncture, Multigated Acquisition Scan, Venetoclax, Vincristine
- Drug · Procedure · Biological
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 12 Years to 55 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Fibrodysplasia Ossificans Progressiva
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 5 Years to 35 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Carcinoma in the Liver
- Interventions
- Biopsy, Biospecimen Collection, Cemiplimab, Computed Tomography, Magnetic Resonance Imaging, Transarterial Radioembolization, Yttrium Y 90 Resin Microspheres
- Procedure · Biological · Radiation
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Cigarette Smoking-Related Carcinoma
- Interventions
- Avoidance, Biospecimen Collection, Cigarette Smoking, Eye Movement Measurement, Healthcare Activity, Questionnaire Administration, Refrain from Smoking, Vaping, Standardized E-Cigarette Nicotine Administration
- Behavioral · Procedure · Other + 1 more
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 21 Years to 50 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Childhood Astrocytoma, Childhood Diffuse Intrinsic Pontine Glioma, Childhood Diffuse Midline Glioma, Childhood Glioblastoma, Childhood Malignant Glioma
- Interventions
- ATM Kinase Inhibitor AZD1390, Biospecimen Collection, Magnetic Resonance Imaging, Radiation Therapy, Survey Administration
- Drug · Procedure · Radiation + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 12 Months to 22 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more
- Conditions
- Total Shoulder Arthroplasty, Shoulder Infection, Povidone Iodine
- Interventions
- sterile saline solution, Surgiphor, Sample Collection
- Drug · Procedure
- Lead sponsor
- Rothman Institute Orthopaedics
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 126 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Interventions
- Biospecimen Collection, Cemiplimab, Cetuximab Sarotalocan Sodium, Computed Tomography, Electronic Health Record Review, Endobronchial Ultrasound Bronchoscopy, Magnetic Resonance Imaging, Photoimmunotherapy, Positron Emission Tomography, Robotic Bronchoscopy, Video-Assisted Thoracic Surgery
- Procedure · Biological · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma
- Interventions
- Biospecimen Collection, Extended Release Metformin Hydrochloride, Monitoring, Nutritional Assessment, Short-Term Fasting
- Procedure · Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Friedreich Ataxia, Healthy Volunteers
- Interventions
- Buccal Swabs, Blood Draws and Skin Punch Biopsy
- Diagnostic Test
- Lead sponsor
- Larimar Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Eatontown, New Jersey
- Conditions
- Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Serous Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IIIA Fallopian Tube Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Primary Peritoneal Cancer AJCC v8, Stage IIIA1 Fallopian Tube Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Fallopian Tube Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Fallopian Tube Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Primary Peritoneal Cancer AJCC v8, Stage IIIC Fallopian Tube Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8
- Interventions
- Carboplatin, Cisplatin, Cytoreductive Surgery, Hyperthermic Intraperitoneal Chemotherapy, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration, Biospecimen Collection, Diagnostic Imaging
- Drug · Procedure · Other
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Mammography Screening, Breast Density
- Interventions
- Biospecimen Collection, Magnetic Resonance Imaging, Mammogram, Survey Administration, Ulipristal Acetate
- Procedure · Other · Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Adenocarcinoma, Advanced Primary Peritoneal Carcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing, Elimusertib, Gemcitabine
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 3
- States / cities
- Bethesda, Maryland • Boston, Massachusetts
- Conditions
- Foregut Neuroendocrine Tumor, Hindgut Neuroendocrine Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Neuroendocrine Tumor, Midgut Neuroendocrine Tumor G1, Neuroendocrine Tumor G2, Recurrent Digestive System Neuroendocrine Tumor G1, Regional Digestive System Neuroendocrine Tumor G1
- Interventions
- Biospecimen Collection, Computed Tomography, Echocardiography Test, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pazopanib Hydrochloride, Placebo Administration, Quality-of-Life Assessment, X-Ray Imaging
- Procedure · Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 412
- States / cities
- Anchorage, Alaska • Scottsdale, Arizona • Anaheim, California + 263 more
- Conditions
- Alzheimer Disease
- Interventions
- Not listed
- Lead sponsor
- Banner Health
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Echocardiography Test, Multigated Acquisition Scan, Osimertinib, Radiologic Examination
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Interventions
- Biospecimen Collection, Letermovir
- Procedure · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Oakland, California • San Francisco, California + 28 more